newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC

  • Financial Performance:

    • As a pre-revenue clinical-stage company, Cardiff Oncology reported no revenue or earnings; financial metrics focus on liquidity.
    • Cash balance stands at approximately $34 million (as of end of Q3), with runway extending through Q3 2027.
    • No specific debt, deferred revenue, or cash flow generation data provided as the company is in development stages.
  • Guidance and Future Outlook:

    • Targeting the start of the Phase 3 registration trial for Onvancitib in first-line metastatic RAS-mutated colorectal cancer (mCRC) in Q1 2027, utilizing a staged initiation approach.
    • Regulatory pathway includes potential for accelerated approval based on Overall Response Rate (ORR) and full approval based on Progression-Free Survival (PFS).
    • Awaiting final feedback from European regulators regarding the Phase 3 design and endpoints.
    • Long-term goal is to establish a new treatment paradigm for the ~50% of mCRC patients with RAS mutations, a population with no approved targeted therapies in 20 years.
  • Business Segments and Product Lines:

    • Lead Asset (Onvancitib): A selective PLK1 inhibitor receiving Fast-Track designation (announced Friday prior to call) and Orphan Drug designation for Chronic Myelomonocytic Leukemia (CMML) and Small Cell Lung Cancer (SCLC).
    • Primary Indication: Phase 2 trial (CARD004) results support Phase 3 enrollment of Onvancitib (30mg) + FOLFIRI + Bevacizumab for first-line mCRC with pan-RAS mutations.
    • Secondary Indications: Promising monotherapy signals observed in relapsed/refractory CMML (40% response rate) and SCLC; data to be updated at the upcoming American Society of Hematology (ASH) meeting.
    • Strategic Shift: Focus on first-line setting for RAS-mutated mCRC, distinguishing from competitors targeting Microsatellite Stable (MSS) or G12C-specific populations.
  • Market and Competitive Landscape:

    • Market Opportunity: Addresses ~50% of mCRC patients harboring RAS mutations (NRAS, KRAS), a high-unmet-need segment with historically poor overall survival.
    • Competitive Differentiation: Unlike competitors pursuing immunotherapy (PD-1/PD-L1 + VEGF) or KRAS G12C inhibitors (limited to a fraction of RAS mutants), Cardiff targets the entire RAS-mutated population.
    • Market Gap: No novel targeted therapies approved for this indication in the last two decades; standard of care remains chemotherapy and Bevacizumab (now generic).
    • Mechanism of Action: Onvancitib demonstrates synergy with Irinotecan by inhibiting HIF-1-alpha (anti-angiogenesis) and blocking PLK1-mediated DNA damage repair, creating a "two-punch" effect.
  • Risks and Challenges:

    • Trial Execution: Phase 3 study relies on pending funding; initiation is contingent on securing sufficient capital before Q1 2027.
    • Regulatory Uncertainty: Final approval depends on the maturation of PFS data in the Phase 3 trial; accelerated approval is contingent on compelling ORR and durability data.
    • Clinical Risk: The Phase 2 study was not powered for PFS, requiring the larger Phase 3 trial to confirm statistical significance and long-term benefit.
    • Competitive Landscape: Risk that other companies targeting MSS populations or specific G12C mutations may capture market share before Onvancitib achieves approval.
  • Management Commentary and Tone:

    • Tone: Highly confident and optimistic, emphasizing "compelling" efficacy data and a clear path to market.
    • CEO Commentary: Mani Mohindru highlighted the 70%+ ORR vs. 42% in controls and the ability to enable curative surgery in a subset of patients.
    • Regulatory Relationship: Praised FDA collaboration, noting successful End-of-Phase 2 meetings that validated the Phase 3 design, dose (30mg), and chemo backbone (FOLFIRI/Bev).
    • Operational Readiness: Management expressed confidence in CRO selection and readiness to commence trials pending funding.
  • Analyst Questions and Answers:

    • Note: Specific analyst Q&A details were not included in the provided transcript text; the section reflects the management presentation's summary of interactions.
    • Regulatory Feedback: Confirmed FDA agreement on using ORR for accelerated approval and PFS for full approval within a single study.
    • Chemo Selection: Management explained the selection of FOLFIRI over FOLFOX due to the mechanistic synergy between Irinotecan and Onvancitib (HIF-1-alpha inhibition and DNA repair blockade), whereas FOLFOX (Oxaliplatin) lacks this synergy.
  • Other Key Points:

    • Durability: Patients on the 30mg Onvancitib + FOLFIRI arm have remained on treatment for >21 months; median PFS has not been reached in the treatment arm compared to 11 months in the control arm.
    • Surgery Potential: A notable number of patients in the treatment arm achieved tumor shrinkage sufficient to undergo curative-intent surgery, a rare outcome in first-line mCRC.
    • Broad Enrollment: Phase 2 included high-risk patients with liver metastases and multi-organ involvement, demonstrating efficacy across the board regardless of baseline characteristics.
    • Mechanism Validation: Preclinical data confirmed that RAS-mutated cancers rely heavily on PLK1, validating the synthetic lethality approach.
Company
CARDIFF ONCOLOGY INC
Keywords
CARDIFF ONCOLOGY INC